It is interesting to note that, in spite of some influential publications from the early 1970s (26, 27) that studied tetrabenazine as a treatment for TD, the interest in VMAT-2 inhibitors had remained dormant for more than four decades. The gene discussed is SLC18A2; the disease is thanatophoric dysplasia.